title: [Therapy of chronic hepatitis B and C].
abstract: 10% of patients infected with the hepatitis B virus develop a chronic hepatitis. The only approved therapy is interferon-alpha, which leads in 30-40% to a HbeAg/anti-Hbe Seroconversion. In contrast, the infection with the hepatitis C virus leads to a chronic hepatitis in over 80%. Here again interferon-alpha is the only approved drug to treat these patients. A sustained normalisation of transaminases and a sustained virological response can be achieved in 20 to 40% at most. In view of these unsatisfactory treatment results, new treatment options are currently being evaluated for both infections. Treatment with nucleoside analogues are being tested in patients with chronic hepatitis B and for the treatment of chronic hepatitis C a combination treatment seems most promising.
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D019694:Hepatitis B, Chronic / Q000628:therapy*; D019698:Hepatitis C, Chronic / Q000628:therapy*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D008111:Liver Function Tests; D016896:Treatment Outcome